Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: A patient-reported outcomes survey

被引：37
作者：
Weinke T.
Edte A. [1 ]
Schmitt S. [2 ]
Lukas K. [3 ]
机构：
[1] TNS Healthcare, GmbH, 80687 München
[2] Sanofi Pasteur MSD, 69181 Leimen
[3] Sanofi Pasteur MSD, 69367 Lyon cedex 07
来源：
Journal of Public Health | 2010年 / 18卷 / 4期
关键词：
Herpes zoster; Pain; Post-herpetic neuralgia; Quality of life; Survey;
D O I：
10.1007/s10389-010-0323-0
中图分类号：
学科分类号：
摘要：
Background The impact of herpes zoster (HZ) and postherpetic neuralgia (PHN) on patients' quality of life (QoL) is currently poorly documented. Subjects and methods Telephone interviews in Germany identified patients =50 years old with painful HZ diagnosed during the previous 5 years. Bespoke questions evaluated previous HZ episodes. Results Of 11,009 respondents, 280 met the screening criteria, and 32 (11%) developed PHN. PHN was associated with significantly worse outcomes than HZ (all P<0.05). Mean pain scores associated with PHN and HZ, respectively, were 7.1 and 6.2 (average) and 8.2 and 7.0 (worst). Many patients with PHN (91%) and HZ (73%) experienced problems with daily activities, including work, studies, housework, family and leisure activities. Mean pain interference scores in patients with PHN versus HZ were highest for sleep (6.5 versus 4.9), normal work (6.1 versus 4.4) and mood (5.9 versus 4.4). Most employed interviewees with PHN (70%) and HZ (64%) stopped work during the disease. Pain andQoL outcomes were not significantly different between all patients versus those diagnosed during the previous 12months or between patients aged 50-59 years versus ≤60 years. Conclusions HZ causes substantial pain, which seriously interferes with many aspects of daily life, particularly in patients with PHN. © The Author(s) 2010.
引用
收藏
页码：367 / 374
页数：7
相关论文
共 39 条
  • [1] Arvin A., Aging, immunity, and the varicella-zoster virus, N Engl J Med, 352, pp. 2266-2267, (2005)
  • [2] Bowsher D., The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population, Eur J Pain, 3, pp. 335-342, (1999)
  • [3] Breuer J., Whitley R., Varicella zoster virus: Natural history and current therapies of varicella and herpes zoster, Herpes, 14, SUPPL. 2, pp. 25-29, (2007)
  • [4] Brisson M., Edmunds W.J., Epidemiology of varicella-zoster virus in England and Wales, J Med Virol, 70, SUPPL. 1, (2003)
  • [5] Brisson M., Edmunds W.J., Law B., Et al., Epidemiology of varicella zoster virus infection in Canada and the United Kingdom, Epidemiol Infect, 127, pp. 305-314, (2001)
  • [6] Brisson M., Pellissier J.M., Camden S., Quach C., De Walls P., The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia, Hum Vaccin, 4, pp. 238-245, (2008)
  • [7] Chidiac C., Bruxelle J., Daures J.P., Et al., Characteristics of patients with herpes zoster on presentation to practitioners in France, Clin Infect Dis, 33, pp. 62-69, (2001)
  • [8] Choo P.W., Galil K., Donahue J.G., Walker A.M., Spiegelman D., Platt R., Risk factors for postherpetic neuralgia, Arch Intern Med, 157, pp. 1217-1224, (1997)
  • [9] Christo P.J., Hobelmann G., Maine D.N., Post-herpetic neuralgia in older adults: Evidence-based approaches to clinical management, Drugs Aging, 24, pp. 1-19, (2007)
  • [10] Coplan P.M., Schmader K., Nikas A., Et al., Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory, J Pain, 5, pp. 344-356, (2004)
1234